CC-92328
- Generic Name
- CC-92328
Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Celgene
- Target Recruit Count
- 26
- Registration Number
- NCT04975399
- Locations
- 🇪🇸
Local Institution - 302, Pamplona, Navarra, Spain
🇨🇦Local Institution - 204, Edmonton, Alberta, Canada
🇺🇸Local Institution - 105, Scottsdale, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath